ClinicalTrials.gov
ClinicalTrials.gov Menu

Thymic Stromal Lymphopoietin (TSLP) in Vitiligo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03367273
Recruitment Status : Completed
First Posted : December 8, 2017
Last Update Posted : December 20, 2017
Sponsor:
Information provided by (Responsible Party):
Maha Fathy Elmasry, Cairo University

Brief Summary:
study & verify the hypothesis of the involvement of TSLP in the pathogenesis of vitiligo in comparison to their levels in the healthy control persons.

Condition or disease Intervention/treatment Phase
Vitiligo Other: skin biopsy Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Study of the Cutaneous Expression of Thymic Stromal Lymphopoietin (TSLP) in a Sample of Vitiligo Patients
Actual Study Start Date : January 2017
Actual Primary Completion Date : July 2017
Actual Study Completion Date : July 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitiligo

Arm Intervention/treatment
Experimental: vitiligo patients Other: skin biopsy
Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject

Experimental: controls Other: skin biopsy
Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject




Primary Outcome Measures :
  1. Expression levels of TSLP in patients of Vitiligo. [ Time Frame: 7 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • • Patients with generalized non-segmental vitiligo.

    • Both sexes.
    • Age < 18 years old age.
    • New cases or cases not receiving any medication for at least 3 months ago.

Exclusion Criteria:

  • • Age: Patients < 18 years.

    • Segmental or universal vitiligo.
    • Pregnant and lactating females. Autoimmune diseases

Responsible Party: Maha Fathy Elmasry, Dr, Cairo University
ClinicalTrials.gov Identifier: NCT03367273     History of Changes
Other Study ID Numbers: Dermatology 2
First Posted: December 8, 2017    Key Record Dates
Last Update Posted: December 20, 2017
Last Verified: December 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Vitiligo
Hypopigmentation
Pigmentation Disorders
Skin Diseases